NFKB1 and cancer: We found that the NFKB1 −94ins/del ATTG promoter polymorphism was significantly increased cancer risk in homozygote (II vs. DD, OR = 1.259, 95% CI = 1.068-1.485), recessive (II vs. ID+DD, OR = 1.140, 95% CI = 1.029-1.263) and allele (I vs. D, OR = 1.109, 95% CI = 1.025-1.199) genetic models.